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ABSTRACT
Venous thromboembolic disease is a major global cause 
of morbidity and mortality. An estimated 10 million 
episodes are diagnosed yearly; over half of these 
episodes are provoked by hospital admission/procedures 
and result in signiicant loss of disability adjusted life 
years. Temporary lower limb immobilisation after injury is 
a signiicant contributor to the overall burden of venous 
thromboembolism (VTE). Existing evidence suggests 
that pharmacological prophylaxis could reduce overall 
VTE event rates in these patients, but the proportional 
reduction of symptomatic events remains unclear. Recent 
studies have used different pharmacological agents, 
dosing regimens and outcome measures. Consequently, 
there is wide variation in thromboprophylaxis strategies, 
and international guidelines continue to offer conlicting 
advice for clinicians. In this review, we provide a 
summary of recent evidence assessing both the 
clinical and cost effectiveness of thromboprophylaxis 
in patients with temporary immobilisation after injury. 
We also examine the evidence supporting stratiied 
thromboprophylaxis and the validity of widely used risk 
assessment methods.
CASE 1
A 60- year- old woman attends your department after 
a fall downstairs, injuring her right ankle. X- rays 
confirm a Weber B fracture to the lateral malleolus 
without talar shift. There is no pain to the medial 
aspect. The orthopaedic plan is for below- knee 
plaster immobilisation in a non- weight- bearing cast, 
conservative management and outpatient review in 
710 days time. On further assessment, a body 
mass index (BMI) of 35 is apparent, along with a 
history of chronic obstructive pulmonary disease.
CASE 2
A 25- year- old man attends your department after a 
crush injury to his left foot sustained at work. X- rays 
reveal undisplaced fourth and fifth metatarsal neck 
fractures. The orthopaedic team advise a walking 
boot and to allow partial weight bearing as toler-
ated until outpatient review later that week. On 
further assessment, the patient has no other medical 
history and no family history of venous thrombo-
embolism (VTE). He takes no medications. Despite 
analgesia in the department, he remains unable to 
put any weight through the affected limb.
QUESTION
 Should these patients be offered thromboprophy-
laxis to reduce their short- term risk of VTE?
To answer that question, we will provide a short 
summary of the problem, followed by a review 
of the evidence and a practical guide to decision- 
making and intervention in these clinical scenarios.
BACKGROUND
VTE is a significant global health burden, with 
incident events alone costing the UK an esti-
mated £640 million and the USA an estimated 
$710 billion each year.1 2 Within the last decade, 
VTE has resulted in more deaths than prostate 
cancer, breast cancer, road traffic accidents and 
AIDS combined.3
Temporary immobilisation after injury accounts 
for approximately 2% of all VTE cases in registry 
data.4 These cases are potentially preventable 
with early pharmacological thromboprophylaxis. 
However, it is unclear which patients will benefit 
from such intervention, which will be harmed, 
whether clinical outcomes are improved as a result 
of treatment and whether prophylaxis is cost- 
effective. As a result, international guidelines 
continue to recommend different management 
options; the UK advises routine assessment and 
individualised prescribing, for example, whereas 
US guidelines advise against thromboprophylaxis in 
this population.5 6
This issue was recently highlighted as a research 
priority for emergency medicine, through the 
James Lind Alliance Priority Setting Partnership in 
the UK.7 While the debate continues, case report 
data and media coverage continue to highlight 
recurrent and tragic outcomes.8 9 It remains unclear 
whether these tragedies were avoidable. In many 
regions, legal rulings and recommendations by the 
coroner/medical examiner delivered with the aim 
of avoiding future deaths have forced the clinical 
agenda without recourse to scientific evidence.10 
Practice remains variable with differing levels of 
engagement and awareness, despite the relative 
frequency of the problem. It is imperative that a 
cross- specialty consensus is reached on manage-
ment of VTE risk, to ensure that clinicians and 
patients can be adequately informed and counselled 
on the merits of intervention.
This article summarises recent work on this topic 
and provides pragmatic guidance and decision 
support for clinicians.
What is the risk of VTE following lower limb 
injury and temporary immobilisation?
A recent Cochrane review on this topic suggests wide 
variation in the incidence of VTE following lower 
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Table 1 Predicted clinical outcomes per 100 000 patients with lower limb immobilisation due to injury
Outcomes at 6 months per 100 000 patients Outcomes at 5 years per 100 000 patients
Fatal 
PE
Fatal 
bleed
Non- fatal 
ICH
Other 
major 
bleed*
Non- fatal 
PE
Symptomatic 
DVT
Asymptomatic 
DVT PTS
PE 
survivor 
with 
CTEPH
PE 
survivor 
without 
CTEPH
ICH 
survivor
Dead 
(any 
cause)
No 
prophylaxis
12 9 5 26 415 907 7052 1859 11 397 5 1133
Prophylaxis 7 12 8 35 225 492 3820 1007 6 215 7 1129
*Patients having other major bleeds could also have a DVT or non- fatal PE.
CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; ICH, intracranial haemorrhage; PE, pulmonary embolism; PTS, post- thrombotic syndrome.
limb immobilisation without thromboprophylaxis, reporting a 
range between 4.3% and 40.0% within the literature.11 These 
figures are based on the outcome of any VTE, including routine 
screening and detection of isolated distal deep vein thrombosis 
(DVT). There is ongoing debate regarding the clinical rele-
vance of such a composite endpoint and the sensitivity of the 
contributing diagnostics.1214 Of more importance to clinicians 
and patients is the incidence of morbidity after immobilisation. 
This is more challenging to define but suggested by many to be 
the incidence of only clinically relevant or symptomatic VTE, 
warranting repeat hospital attendance and/or intervention.15 
Accurate estimates of this endpoint suffer from limitations in the 
injured population regarding subjectivity. When should a clini-
cian or patient suspect VTE in a leg that is painful and swollen 
at baseline from injury? However, recent studies with trans-
parent reporting of clinically relevant outcomes demonstrate a 
high level of consistency. The recent Cochrane review extracted 
data from six studies1621 involving just under 3000 randomised 
patients; symptomatic VTE occurred in 1.8%5.5% of conser-
vatively managed patients. These results suggest that without 
thromboprophylaxis, approximately 1 in every 50 patients will 
suffer a symptomatic VTE event (including symptomatic distal 
and proximal DVT and pulmonary embolism (PE)) following 
temporary immobilisation after injury. This is likely to be an 
underestimate given the range previously mentioned, the exclu-
sion of high- risk patients from trial design and the general health 
equity of patients willing to engage with research.
Is thromboprophylaxis clinically effective?
Can pharmacological thromboprophylaxis reduce this morbidity 
burden and, if so, by what margin? We performed a recently 
updated systematic review and network meta- analysis to compare 
any pharmacological intervention against control for this defined 
population.22 23 This review included the Prevention of Throm-
bosis after Lower Leg Plaster Cast (POT- CAST) trial,21 which 
has reignited debate on this important topic, and other recent 
randomised studies assessing the novel use of fondaparinux for 
this indication. We identified 13 trials with 6857 patients suit-
able for inclusion.1621 2430 Interventions included prophylactic 
dose low molecular weight heparin (LMWH) or fondaparinux 
only. We examined four additional trials that had been excluded 
from the previous Cochrane review and one trial published 
subsequently. We found no trial evidence examining the use of 
direct oral anticoagulants (DOACs) in this situation. Risk of bias 
was present in all included studies. We found that both LMWH 
and fondaparinux significantly reduced the odds of clinically 
detected DVT, PE and any VTE. Intervention appeared to halve 
the risk of VTE across all classifications.23
It follows that the absolute 2% risk of clinically significant 
VTE following temporary immobilisation after injury can be 
effectively halved to 1% with prophylactic dose anticoagulation. 
Although this may represent a potentially high number needed 
to treat, this value would depend primarily on baseline risk 
(which is likely to vary within the population) and also would be 
considered in the context of prevalence. Approximately 70 000 
patients are immobilised and discharged from EDs in the UK 
alone every year.23 Even a 1% absolute risk reduction in the VTE 
event rate in this cohort would therefore represent prevention 
of 700 clinically relevant VTE events. Assuming these events 
would be detected and treated as provoked VTE in the absence 
of thromboprophylaxis, they would incur 63 000 patient days of 
therapeutic dose anticoagulation, with accompanying costs and 
harms.
What are the harms of thromboprophylaxis?
Clear definitions are now in place for the identification and 
classification of bleeding events in trials of anticoagulation and 
thromboprophylaxis.3133 Using these, our above systematic 
review found limited evidence of harm from prophylactic dose 
anticoagulation in this population. Only four major bleeding 
events were identified in total, with insufficient evidence of an 
increase within the LMWH group (OR 1.45, 95% CrI 0.08 to 
32.17). Although these results are inconclusive given the low 
frequency of events, only four events within a trial sample of just 
under 7000 patients provide some reassurance on safety.
Minor bleeding as a secondary outcome varied across the 
population, being found in 0%10.5% of patients treated with 
LMWH, in 0%1.5% of patients treated with fondaparinux and 
in 0%6.8% of the control groups. No cases of death attribut-
able to VTE or intervention were identified within the study, and 
in those trials monitoring for the incidence of heparin- induced 
thrombocytopenia (HIT), no cases were detected. The most 
common adverse event of infection appeared equal between 
control and intervention groups when strictly defined.21
Do the benefits of thromboprophylaxis justify the risks?
Thromboprophylaxis reduces the risk of thromboembolism but 
may increase the risk of bleeding. Our data were inconclusive 
on this latter aspect, but it remains one of the primary clinical 
concerns regarding the use of thromboprophylaxis. We under-
took decision- analytic modelling to determine how these risks 
might compare in people undergoing lower limb immobilisation 
due to injury.34 Table 1 summarises the results. The risk of fatal 
PE (which often drives decisions and recommendations regarding 
thromboprophylaxis) is very small, and the reduction in this risk 
associated with thromboprophylaxis is roughly matched by an 
increase in the risk of fatal bleeding or non- fatal intracranial 
haemorrhage. Overall, the risk of death or non- fatal intracranial 
haemorrhage is about 1 in 4000, whether thromboprophylaxis is 
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Table 2 Summary of design characteristics and threshold levels of identiied RAMs
Risk assessment model Acronym/descriptor Derivation Design
Incorporation of 
bleeding risk?
Number of 
variables
Threshold 
(suggested 
cut- point)
Attempted 
validation?
Roberts et al42 The GEMNet guideline EC Dichotomous Yes 11 N/A Yes
Keenan et al49 The Plymouth Rule EC Ordinal No 14 >2 Yes
Nemeth et al36 The L- TRiP(cast) score Regression Ordinal No 14 >8 Yes
Saragas et al41 The modiied Caprini score EC Ordinal No 36 >1 No
Eingartner et al45 N/A EC Ordinal No 9 >1 No
Haque et al46 N/A EC Ordinal No 14 >2 No
Giannadakis et al44 N/A EC Dichotomous No 12 N/A No
EC, Expert Consensus; GEMNet, Guidelines in Emergency Medicine Network; L- TRIP(cast), Leiden Thrombosis Risk in Plaster (cast); N/A, not applicable; RAM, risk assessment 
method.
given or not. These are tragic events and, given the large popula-
tion undergoing immobilisation, will occur with some frequency. 
However, our analysis suggests that thromboprophylaxis will 
not markedly change their incidence.
The main benefits of thromboprophylaxis lie in preventing 
non- fatal PE, symptomatic DVT and, in particular, asymptomatic 
DVT. Benefits for patients are assumed to accrue in the form of 
reduced long- term complications, particularly post- thrombotic 
syndrome. We estimated that, taking all effects into account, 
thromboprophylaxis results in 0.015 additional quality- adjusted 
life years (QALYs) per patient treated (95% credible interval 
(CrI 0.004 to 0.029), indicating an overall benefit. However, it 
is uncertain whether a reduced risk of asymptomatic DVT leads 
to a reduced risk of post- thrombotic syndrome, so this finding 
should be treated with some caution.35
Is thromboprophylaxis cost-effective?
Given the cost implications of prophylaxis, the low absolute 
event rate and the potential implications of any recommen-
dations it is necessary to examine the cost effectiveness of 
this intervention. Our recent work for the Health Technology 
Assessment Programme examined this in detail.23 We examined 
the wider literature to generate estimates of incidence for VTE, 
post- thrombotic syndrome, chronic thromboembolic pulmo-
nary hypertension, intracranial haemorrhage, major bleeding 
and death among other potential outcomes. We subsequently 
assigned costs to these outcomes then designed a decision tree 
and used a Markov model to generate estimates of overall cost 
effectiveness.
Based on the mean costs and QALYs gained, we found an 
incremental cost- effectiveness ratio (ICER) for thromboprophy-
laxis compared with no thromboprophylaxis of £13 524. Based 
on standard thresholds used by the National Institute for Health 
and Care Excellence (NICE) in England, this value would fall 
below the ICER threshold of £20 000 and, as such, the interven-
tion would broadly be considered as cost- effective.
We went on to examine the potential cost effectiveness of 
using a risk assessment method (RAM) to recommend stratified 
thromboprophylaxis. Several published RAMs were available 
with threshold prognostic accuracy data, to inform the model-
ling.36 37 We found that a RAM could potentially improve the 
cost effectiveness of thromboprophylaxis, depending on the 
threshold score at which thromboprophylaxis would be given. 
The optimal threshold, assuming the RAM operated with diag-
nostic characteristics similar to the Leiden Thrombosis Risk in 
Plaster (cast) (L- TRiP(cast)) score, would result in a sensitivity 
of 84%89% and a specificity of 46%55% for predicting VTE.
Can we safely risk stratify patients to maximise clinical and 
cost effectiveness?
Using risk factors to tailor thromboprophylaxis recommenda-
tions is a common strategy in hospitals.38 There is face validity 
to the concept of risk prediction and tailored therapy in tempo-
rary lower limb immobilisation, which is strengthened by the 
low absolute risk and costs/inconvenience of treatment.15
We examined the literature to try and identify whether estab-
lished individual VTE risk factors can predict the likelihood 
of subsequent disease in this ambulatory cohort of patients. A 
further systematic review was conducted, identifying 15 studies 
and 80 678 patients for inclusion. Meta- analysis of data was not 
possible due to significant variation between studies regarding 
data collection methods. All studies were deemed to be at 
moderate to severe risk of bias. We found advancing age and 
injury pattern to be consistently associated with increased VTE 
risk. BMI was the third most consistent individual risk high-
lighted, although overall results were conflicting. A total of 12 
other risk factors analysed did not demonstrate any consistency 
in association with VTE across the dataset.39 A subsequent publi-
cation supports our findings, reporting injury pattern, family 
history and BMI to be the individual risk factors most associated 
with VTE risk, among the POT CAST trial cohort.40
We conducted a further systematic review and engaged topic 
experts to try and identify available RAMs for use in this popu-
lation. This work identified seven RAMs, three of which have 
undergone attempted external validation.36 4146 Variation and 
essential characteristics of the identified RAMs are presented 
in table 2. All studies looking to derive or externally validate a 
RAM were deemed to be at high risk of bias and did not report 
discrimination or calibration within an appropriate external 
population.
Prognostic accuracy measures for the three scores evaluated in 
two validation studies are presented in table 3. RAM sensitivity 
varies from 57.1% to 92.6% and specificity varies from 4.76% 
to 60.8%. As an ordinal score with additional validation data, 
The L- TRiP(cast) RAM is displayed in this table using thresh-
olds denoting optimal performance and to allow direct compar-
ison with other validated scores. The area under the receiver 
operating characteristic curve for the L- TRiP(cast) score ranged 
from 0.77 (95% CI 0.66 to 0.87) in the derivation cohort to 
0.77 (95% CI 0.58 to 0.96) and 0.95 (95% CI 0.91 to 0.99) in 
the two subsequent validation cohorts. In addition, subsequent 
retrospective evaluation of the L- TRiP(cast) score within the 
POT- CAST cohort reports a lower area under the curve value 
of 0.69 (95% CI 0.58, 0.80).40 As such, although the concept 
of a RAM is intuitive in this situation, the available supporting 
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Table 3 Diagnostic performance of the L- TRiP(cast), GEMNet and 
Plymouth risk assessment models
Author Roberts et al Keenan et al Nemeth et al
Risk assessment model GEMNet Plymouth L- TRiP(cast) 
with a
cut- point of 8 
or above
L- TRiP(cast) 
with a
cut- point of 9 
or above
Sensitivity (95% CI) 85.7%
(62.6% to 96.2%)
57.1%
(33.4% to 77.4%)
92.6% 80.8%
Speciicity (95% CI) 4.76%
(0.2% to 25.9%)
52.4%
(30.3% to 73.6%)
39.7% 60.8%
Positive predictive value 
(95% CI)
47.4%
(31.3% to 64.0%)
54.5%
(32.7% to 74.9%)
3.8% 5.0%
Negative predictive value 
(95% CI)
25.0%
(1.3% to 78.1%)
55.0%
(32.0% to 76.2%)
99.5% 99.2%
Likelihood ratio positive 
(95% CI)
0.90
(0.73 to 1.10)
1.20
(0.67 to 2.15)
1.5 2.1
Likelihood ratio negative 
(95% CI)
3.00
(0.16 to 55.31)
0.81
(0.46 to 1.46)
0.2 0.3
Proportion receiving 
thromboprophylaxis 
(95% CI)
90.5%
(76.5% to 96.9%)
52.4%
(36.6% to 67.7%)
87.8% 74.7%
evidence is weak. Further RAMs (such as the Trauma, Immo-
bilisation and Patients Characteristics (TIP) score) continue to 
be published using Delphi consensus methodology and other 
derivation techniques, reporting improved performance metrics 
on internal validation.47 All proposed RAMS remain in need of 
robust external validation.
What are the key uncertainties and challenges moving 
forward?
Can I use a DOAC for this indication?
There is no trial evidence examining the use of DOAC medica-
tions in this clinical scenario. As such, there are no available data 
on the clinical or cost effectiveness of these drugs. Any such use 
would be off licence and approved as part of a trust protocol 
using local pharmacy and thrombosis committee governance 
structures.
Many trusts have taken this option and are starting to publish 
prospective datasets recording their experience.10 48 Evaluation 
of this strategy with organisational support and careful oversight 
is to be encouraged and will provide estimates of effectiveness 
and safety that may support the case for future research.
 Does this evidence apply to temporary splints as well as plaster 
casts?
The majority of research in this area focusses on immobilisation 
in plaster. As such, all estimates of effectiveness are not necessarily 
generalisable to other forms of immobilisation, which may allow 
partial weight bearing or less restriction in mobility. However, 
a caution should be noted here; often patients are treated with 
advice to partially weight bear when they clearly cannot do so. 
These patients remain at risk of VTE through immobility. NICE 
guideline NG89 currently defines lower limb immobilisation as 
any clinical decision taken to manage the affected limb in a way 
that would prevent normal weight- bearing status, or use of that 
limb, or both.5 Many patients who are managed with crutches 
and a splint would meet this definition and therefore justify risk 
assessment. This does not mandate prophylaxis but does recom-
mend consideration of risk and shared decision- making (SDM).
 Which RAM is best?
The evidence provided earlier highlights the lack of external 
validation data for any RAM. The Guidelines in Emergency 
Medicine Network (GEMNet), Plymouth rule, L- TRiP(cast) and 
TIP score all appear to have limited supporting/validation data 
and variable strengths and weaknesses.36 42 47 49 If using a RAM, 
clinicians should focus on consistency and serial audit to ensure 
appropriate use of the RAM, proportional use of thrombopro-
phylaxis, patient outcomes and national benchmarking. For 
transparency and comparison, an example score sheet for each 
of the four RAMs previously mentioned can be found in online 
supplementary figures S1- S4.
 Do these patients need blood tests prior to commencement of 
LMWH?
National guidelines from the British Committee for Standards 
in Haematology (BCSH) are clear that any patient receiving any 
form of heparin should have an estimate of baseline renal func-
tion and platelet count recorded.50 These tests have a clear ratio-
nale: ensuring appropriate dosing and agent choice, absence of 
coagulopathy and recording baseline platelet count to clarify the 
degree of any future drop. These tests are equally necessary prior 
to commencement on any DOAC agent. The same BCSH guid-
ance clarifies that adverse events such as HIT are rare enough 
with prophylactic dose LMWH that further routine platelet 
counts are unnecessary, and repeat testing should be based only 
on clinical concern.
 How long should these patients remain on prophylactic 
anticoagulation and who should follow them up?
The vast majority of the trial data pertaining to these patients 
continued prophylactic anticoagulation for the duration of 
immobilisation in plaster and until return to baseline mobility. 
This often constitutes a period of 46 weeks. However, with the 
advent of newer immobilisation strategies and virtual fracture 
clinics, it is becoming clear that many patients are being encour-
aged to mobilise early after injury and often return to weight- 
bearing status and full mobility earlier than initially predicted. 
As such, it is vital that orthopaedic teams have an interest in this 
issue; decisions to remove a plaster cast and encourage mobili-
sation may facilitate earlier cessation of thromboprophylaxis. In 
addition, bleeding problems early in management may adjust the 
risk/benefit profile.
 How do I use SDM in this context?
SDM involves the clinician offering options and describing their 
risks and benefits, the patient expressing his or her preferences 
and values, and then both jointly agreeing on a treatment deci-
sion. Emergency physicians appear supportive of this approach, 
and a number of tools have been developed, or are being devel-
oped, to support SDM in emergency care.51 52 RAMs such as the 
Plymouth rule have been designed to allow potential comple-
tion by patients and to guide subsequent informed discussion. 
However, we are not aware of any published decision tools 
specifically incorporating SDM relevant to thromboprophylaxis 
in lower limb immobilisation. Data presented here could be used 
to support SDM and to develop such a tool.
Cases: outcome
Case 1
This patient has both temporary and permanent risk factors for 
VTE. Her age and BMI are also of concern. She has a Plym-
outh score of 4 and an L- TRIP(cast) score of 10 and would 
meet GEMNet criteria for recommendation of thromboprophy-
laxis. As such, she should be counselled regarding her acutely 
increased risk of VTE. She should be informed that her absolute 
risk is likely to be higher than 2%.
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Guidance regarding the clinical signs and symptoms of VTE 
should be provided in verbal and written form, and measures 
advised to mitigate risk (such as adequate hydration and mobil-
isation of the unaffected limb). The first and second authors 
would offer and prescribe prophylactic dose LMWH or a DOAC, 
respectively, up to the point of next orthopaedic review. The 
patient would be counselled on the minor risk of bleeding and 
informed that any treatment can be revisited at further ortho-
paedic follow- up, depending on clinical progress. A focal point 
of contact for immediate concern would be provided.
Case 2
This patient has temporary but no clear permanent risk factors 
for VTE. He is also young and the immobilisation method 
chosen is less restrictive. He has a Plymouth score of 0 and an 
L- TRIP(cast) score of 3 and would not meet GEMNet criteria 
for recommendation of thromboprophylaxis. He should still be 
informed of a potential VTE risk, but this is likely to be an abso-
lute risk lower than 2%.
Guidance regarding the clinical signs and symptoms of VTE 
should be provided in verbal and written form, and measures 
advised to mitigate risk (such as adequate hydration and mobili-
sation of the affected and unaffected limb). The first and second 
author would not routinely offer prophylactic anticoagulation 
for this clinical scenario, based on the low VTE risk and the 
limited application of the available data to non- rigid immobilisa-
tion. The patient should be informed that any signs or symptoms 
of VTE should be disclosed at further orthopaedic follow- up 
or earlier as required. A point of focal contact for immediate 
concern should be provided.
SUMMARY
In patients with temporary lower limb immobilisation after 
trauma, the absolute risk of symptomatic VTE is low, at approx-
imately 2%. Current evidence suggests that pharmacological 
prophylaxis can significantly reduce this risk. The benefits of 
thromboprophylaxis are achieved mainly through reduction of 
morbidity rather than lives saved. Pharmacological prophylaxis 
appears to be cost- effective.
Risk assessment can help inform SDM and individually tailor 
thromboprophylaxis, but there is limited evidence of external 
validation for any specific method at present. A key aspect of the 
risk assessment process is the sharing of information; clinicians 
must inform patients that there is an increased risk of VTE with 
temporary immobilisation and what the common presenting 
features are, even if the absolute risk is low.
Twitter Daniel Horner @rcemprof
Acknowledgements The authors thank all additional members of the core project 
group for HTA 15/187/06 for input and commentary throughout the work, including 
Shan Bennet and Robin Pierce- Williams for providing patient and public involvement. 
The authors also thank Mark Clowes for his assistance with the initial literature 
searches and article sourcing. We are also indebted to Joanne Hinde for assistance 
with logistics and administration.
Contributors DH and SG conceived the idea for this review and also acted as 
co- chief investigators for HTA 15/187/06. With regard to the wider project, AP 
was responsible for systematic review work; JWS was responsible for the statistical 
aspects; SD was responsible for the decision modelling and cost- effectiveness 
work; and TN, BH, KH and JK provided clinical expertise throughout the project. 
DH and SG were responsible for the drafting of this paper, although all authors 
provided comments on the drafts and read and approved the inal version. DH is the 
guarantor for the paper.
Funding Much of the work cited in this review was funded by the UK National 
Institute for Health Research (NIHR) Health Technology Assessment Programme 
(project number 15/187/06). The views expressed in this review are those of the 
authors and not necessarily those of the NIHR HTA Programme. Any errors are the 
responsibility of the authors. The funders had no role in the study design; collection, 
analysis and interpretation of data; writing of the manuscript; and decision to submit 
the manuscript for publication.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Daniel Horner http:// orcid. org/ 0000- 0002- 0400- 2017
Steve Goodacre http:// orcid. org/ 0000- 0003- 0803- 8444
Sarah Davis http:// orcid. org/ 0000- 0002- 6609- 4287
REFERENCES
 1 House, Of Cet al. The prevention of venous thromboembolism in hospitalised patients 
- second report of session 2004-2005. London: The Stationary Ofice, 2005.
 2 Grosse SD, Nelson RE, Nyarko KA, et al. The economic burden of incident venous 
thromboembolism in the United States: a review of estimated attributable healthcare 
costs. Thromb Res 2016;137:3–10.
 3 ISTH, Steering Cet al. Thrombosis: a major contributor to the global disease burden. J 
Thromb Haemost 2014;12:1580–90.
 4 Bertoletti L, Righini M, Bounameaux H, et al. Acute venous thromboembolism after 
non- major orthopaedic surgery or post- traumatic limb immobilisation. Thromb 
Haemost 2011;105:739–41.
 5 NICE. Venous thromboembolism in over 16S: reducing the risk of hospital- acquired 
deep vein thrombosis or pulmonary embolism (NG89), 2018. Available: https://www. 
nice. org. uk/ guidance/ ng89/ chapter/ Recommendations# terms- used- in- this- guideline 
[Accessed 11 Jun 2019].
 6 Falck- Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTe in orthopedic surgery 
patients: antithrombotic therapy and prevention of thrombosis, 9th ED: American 
College of chest physicians evidence- based clinical practice guidelines. Chest 
2012;141:e278S–325.
 7 Smith J, Keating L, Flowerdew L, et al. An emergency medicine research priority 
setting partnership to establish the top 10 research priorities in emergency medicine. 
Emerg Med J 2017;34:454–6.
 8 Chen L, Soares D. Fatal pulmonary embolism following ankle fracture in a 17- year- old 
girl. J Bone Joint Surg Br 2006;88- B:400–1.
 9 Irish, Times. Coroner to highlight blood clot risks following sudden death of CO Tyrone 
church Minister  Irishnews. com, 2019. Available: https://www. irishnews. com/ news/ 
2018/ 08/ 08/ news/ coroner- to- highlight- blood- clot- risks- following- sudden- death- of- 
co- tyrone- church- minister- 1402184/ [Accessed 11 Jun 2019].
 10 Maclean R, Roberts C. Personal communication. personal email regarding the use of 
DOAC medications as thromboprophylaxis for patients in lower limb plaster, as well 
as description of recent section 28 recommendation by coroner to avoid future deaths 
that risk assessment and thromboprophylaxis for this indication become mandatory 
2017.
 11 Zee AAG, van Lieshout K, van der Heide M, et al. Low molecular weight heparin for 
prevention of venous thromboembolism in patients with lower- limb immobilization. 
Cochrane Database Syst Rev 2017;376.
 12 Horner D, Hogg K, Body R. Should we be looking for and treating isolated calf vein 
thrombosis? Emerg Med J 2016;33:431–7.
 13 Horner D, Hogg K, Body R, et al. The anticoagulation of calf thrombosis (act) project: 
results from the randomized controlled external pilot trial. Chest 2014;146:1468–77.
 14 Jones T, Horner D. Bet 2: striking the right balance: anticoagulation and isolated distal 
deep vein thrombosis. Emerg Med J 2017;34:334–6.
 15 Nemeth B, Cannegieter SC. Venous thrombosis following lower- leg cast 
immobilization and knee arthroscopy: from a population- based approach to 
individualized therapy. Thromb Res 2019;174:62–75.
 16 Bruntink MM, Groutars YME, Schipper IB, et al. Nadroparin or fondaparinux versus no 
thromboprophylaxis in patients immobilised in a below- knee plaster cast (protect): a 
randomised controlled trial. Injury 2017;48:936–40.
 17 Jørgensen PS, Warming T, Hansen K, et al. Low molecular weight heparin (Innohep) as 
thromboprophylaxis in outpatients with a plaster cast. Thromb Res 2002;105:477–80.
 18 Kock H- J, Schmit- Neuerburg KP, Hanke J, et al. Thromboprophylaxis with low- 
molecular- weight heparin in outpatients with plaster- cast immobilisation of the leg. 
The Lancet 1995;346:459–61.
 19 Lapidus LJ, Ponzer S, Elvin A, et al. Prolonged thromboprophylaxis with dalteparin 
during immobilization after ankle fracture surgery: a randomized placebo- controlled, 
double- blind study. Acta Orthop 2007;78:528–35.
copyright.
 o
n
 N
ovem
ber 13, 2019 at Sheffield Uni Consortia. Protected by
http://emj.bmj.com/
Em
erg M
ed J: first published as 10.1136/em
erm
ed-2019-208944 on 6 Novem
ber 2019. Downloaded from
 
6 Horner D, et al. Emerg Med J 2019;0:1–6. doi:10.1136/emermed-2019-208944
Practice review
 20 Lassen MR, Borris LC, Nakov RL. Use of the low- molecular- weight heparin reviparin to 
prevent deep- vein thrombosis after leg injury requiring immobilization. N Engl J Med 
2002;347:726–30.
 21 van Adrichem RA, Nemeth B, Algra A, et al. Thromboprophylaxis after knee 
arthroscopy and Lower- Leg casting. N Engl J Med 2017;376:515–25.
 22 Horner D, Stevens J, Pandor A, et al. Pharmacological thromboprophylaxis to prevent 
venous thromboembolism in patients with temporary lower limb immobilization after 
injury: systematic review and network meta- analysis. J Thromb Haemost 2019.
 23 Pandor A, Horner D, Davis S, et al. Pharmacological thromboprophylaxis for lower 
limb immobilisation after injury: systematic review and economic evaluation. Health 
Technology Assessment. 2018.
 24 Gehling H, Giannadakis K, Lefering R, et al. [Prospective randomized pilot study of 
ambulatory prevention of thromboembolism. 2 times 500 mg aspirin (ASS) vs. clivarin 
1750 (NMH)]. Unfallchirurg 1998;101:42–9.
 25 Goel D, Buckley R, deVries G, et al. Prophylaxis of deep- vein thrombosis in fractures 
below the knee: a prospective randomised controlled trial. The Journal of Bone and 
Joint Surgery 2009;91.
 26 Kujath P, Spannagel U, Habscheid W. Incidence and prophylaxis of deep venous 
thrombosis in outpatients with injury of the lower limb. Haemostasis 1993;23 Suppl 
1:20–6.
 27 Lapidus LJ, Rosfors S, Ponzer S, et al. Prolonged thromboprophylaxis with dalteparin 
after surgical treatment of Achilles tendon rupture: a randomized, placebo- controlled 
study. J Orthop Trauma 2007;21:52–7.
 28 Samama CM, Lecoules N, Kierzek G, et al. Comparison of fondaparinux with 
low- molecular- weight heparin for venous thromboembolism prevention in patients 
requiring rigid or semi- rigid immobilization for isolated non- surgical below- knee 
injury. Annales Francaises de Medecine d'Urgence 2014;4:153–66.
 29 Selby R, Geerts WH, Kreder HJ, et al. A double- blind, randomized controlled trial of the 
prevention of clinically important venous thromboembolism after isolated lower leg 
fractures. J Orthop Trauma 2015;29:224–30.
 30 Zheng X, Li D- Y, Wangyang Y, et al. Effect of chemical thromboprophylaxis on the rate 
of venous thromboembolism after treatment of foot and ankle fractures. Foot Ankle 
Int 2016;37:1218–24.
 31 Kaatz S, Ahmad D, Spyropoulos AC, et al. Deinition of clinically relevant non- major 
bleeding in studies of anticoagulants in atrial ibrillation and venous thromboembolic 
disease in non- surgical patients: communication from the SSC of the ISTH. J Thromb 
Haemost 2015;13:2119–26.
 32 Schulman S, Angeras U, Bergqvist D, et al. Deinition of major bleeding in clinical 
investigations of antihemostatic medicinal products in surgical patients. J Thromb 
Haemost 2010;8:202–4.
 33 Schulman S, Kearon C, et al, Subcommittee on Control of Anticoagulation of 
the Scientiic and Standardization Committee of the International Society on 
Thrombosis and Haemostasis. Deinition of major bleeding in clinical investigations 
of antihemostatic medicinal products in non- surgical patients. J Thromb Haemost 
2005;3:692–4.
 34 Davis S, Goodacre S, Pandor A, et al. Decision- analysis modelling of the effects 
of thromboprophylaxis for people with lower limb immobilisation for injury. Br J 
Haematol 2019.
 35 Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the 
postthrombotic syndrome. Arch Intern Med 2004;164:17–26.
 36 Nemeth B, Adrichem RAvan, Hylckama Vlieg Avan, et al. Venous Thrombosis Risk after 
Cast Immobilization of the Lower Extremity: Derivation and Validation of a Clinical 
Prediction Score, L- TRiP(cast), in Three Population- Based Case–Control Studies. PLoS 
Med 2015;12:e1001899–e99.
 37 Watson U, Hickey BA, Jones HM, et al. A critical evaluation of venous 
thromboembolism risk assessment models used in patients with lower limb cast 
immobilisation. Foot and Ankle Surgery 2016;22:191–5.
 38 Caprini JA, Arcelus JI, Reyna J. Effective risk stratiication of surgical and nonsurgical 
patients for venous thromboembolic disease. Semin Hematol 2001;38:12–19.
 39 Horner D, Pandor A, Goodacre S, et al. Individual risk factors predictive of venous 
thromboembolism in patients with temporary lower limb immobilization due to injury: 
a systematic review. J Thromb Haemost 2019;17:329–44.
 40 Nemeth B, van Adrichem R, Nelissen R, et al. Individualized thromboprophylaxis in 
patients with Lower- Leg cast Immobilization- A validation and subgroup analysis in 
the POT- CAST trial. Thromb Haemost 2019;119:1508–16.
 41 Saragas NP, Ferrao PNF, Jacobson BF, et al. The beneit of pharmacological venous 
thromboprophylaxis in foot and ankle surgery. S Afr Med J 2017;107:327–30.
 42 Roberts C, Horner D, Coleman G, et al. Guidelines in emergency medicine network 
(GEMNet): guideline for the use of thromboprophylaxis in ambulatory trauma patients 
requiring temporary limb immobilisation. Emerg Med J 2013;30:968–82.
 43 Nokes TJCaK J. Venous thromboembolism risk assessment V2. plymouth (Derriford 
Hospital) 2010.
 44 Giannadakis K, Gehling H, Sitter H, et al. Is medicamentous thrombosis prophylaxis 
necessary in conservative outpatient therapy with lower limb injuries? Unfallchirurg 
2000;103:475–8.
 45 Eingartner C, Hontzsch D, Lang E, et al. Individualized prophylaxis for 
thromboembolism in outpatients - A practical way out between ’ever’ and never’? 
Aktuelle Traumatologie 1995;25:1–5.
 46 Haque S, Bishnoi A, Khairandish H, et al. Thromboprophylaxis in ambulatory trauma 
patients with foot and ankle fractures: prospective study using a risk scoring system. 
Foot Ankle Spec 2016;9:388–93.
 47 Douillet D, Nemeth B, Penaloza A, et al. Venous thromboembolism risk stratiication 
for patients with lower limb trauma and cast or brace immobilization. PLoS One 
2019;14:e0217748.
 48 Haque S, Davies MB. Oral thromboprophylaxis in patients with ankle fractures 
immobilized in a below the knee cast. Foot and Ankle Surgery 2015;21:266–8.
 49 Keenan J, Hall MJ, Nokes TJC. A practical VTe risk assessment score tool for patients 
treated with lower limb cast immobilization. Injury Extra 2009;40:199–200.
 50 Baglin T, Barrowcliffe TW, Cohen A, et al. Guidelines on the use and monitoring of 
heparin. Br J Haematol 2006;133:19–34.
 51 Probst MA, Kanzaria HK, Frosch DL, et al. Perceived appropriateness of shared 
decision- making in the emergency department: a survey study. Acad Emerg Med 
2016;23:375–81.
 52 Melnick ER, Probst MA, Schoenfeld E, et al. Development and testing of shared 
decision making interventions for use in emergency care: a research agenda. Acad 
Emerg Med 2016;23:1346–53.
copyright.
 o
n
 N
ovem
ber 13, 2019 at Sheffield Uni Consortia. Protected by
http://emj.bmj.com/
Em
erg M
ed J: first published as 10.1136/em
erm
ed-2019-208944 on 6 Novem
ber 2019. Downloaded from
 
